All In Biotech

Drug Trial Radar · NCT06219941

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY-PanTumour01)

Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 226 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

226

Planned (sponsor's estimate)

Start

Dec 13, 2023

Primary completion

Nov 17, 2026

Study completion Jun 28, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jan 23, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced unresectable or metastatic solid tumours expressing CLDN18.2 .

Conditions

  • Gastric Cancer
  • Gastroesophageal Junction Cancer
  • Biliary Tract Cancer
  • Pancreatic Ductal Adenocarcinoma

Interventions

  • AZD0901Drug

    Antibody-drug conjugate/Biologic

  • 5-FluorouracilDrug

    Chemotherapy agents

  • LeucovorinDrug

    Chemotherapy agents

  • l-leucovorinDrug

    Chemotherapy agents

  • IrinotecanDrug

    Chemotherapy agents

  • Nanoliposomal IrinotecanDrug

    Chemotherapy agents

  • GemcitabineDrug

    Chemotherapy agents

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs), serious AEs (SAEs). Changes from baseline in clinical laboratory parameters, vital signs, ECGs and physical examination. Rate of AEs leading to discontinuation of AZD0901, Occurrence of DLTs.Time frame: 30 days post treatment completion. AE Follow Up for 90 days post AZD0901 discontinuation.
  2. Objective Response Rate (ORR).Time frame: From date of first dose of AZD0901 up until progression, or the last evaluable assessment in the absence of progression (approximately 2 years).

Locations

52 sites in 14 countries. Site status is shown where the registry gives one.

  • Research Site

    Orange, California · Recruiting

  • Research Site

    Palo Alto, California · Recruiting

  • Research Site

    Santa Rosa, California · Recruiting

  • Research Site

    Louisville, Kentucky · Recruiting

  • Research Site

    Commack, New York · Recruiting

  • Research Site

    Providence, Rhode Island · Recruiting

  • Research Site

    Houston, Texas · Recruiting

  • Research Site

    Melbourne, Australia · Recruiting

  • Research Site

    Murdoch, Australia · Recruiting

  • Research Site

    Randwick, Australia · Recruiting

  • Research Site

    Kingston, Ontario, Canada · Withdrawn

  • Research Site

    Toronto, Ontario, Canada · Recruiting

  • Research Site

    Montreal, Quebec, Canada · Recruiting

  • Research Site

    Sherbrooke, Quebec, Canada · Recruiting

  • Research Site

    Changsha, China · Not yet recruiting

  • Research Site

    Chengdu, China · Not yet recruiting

  • Research Site

    Tbilisi, Georgia · Recruiting

  • Research Site

    Chūōku, Japan · Recruiting

  • Research Site

    Kashiwa, Japan · Recruiting

  • Research Site

    Kitaadachi-gun, Japan · Recruiting

  • Research Site

    Kōtoku, Japan · Recruiting

  • Research Site

    Nagoya, Japan · Recruiting

  • Research Site

    Osakasayama-shi, Japan · Recruiting

  • Research Site

    George Town, Malaysia · Recruiting

  • Research Site

    Johor Bahru, Malaysia · Completed

  • Research Site

    Kuala Lumpur, Malaysia · Recruiting

  • Research Site

    Kuala Selangor, Malaysia · Recruiting

  • Research Site

    Kuching, Malaysia · Recruiting

  • Research Site

    Chisinau, Moldova · Recruiting

  • Research Site

    Krakow, Poland · Recruiting

  • Research Site

    Warsaw, Poland · Recruiting

  • Research Site

    Bukit Merah, Singapore · Recruiting

  • Research Site

    Singapore, Singapore · Recruiting

  • Research Site

    Singapore, Singapore · Recruiting

  • Research Site

    Singapore, Singapore · Recruiting

  • Research Site

    Gyeonggi-do, South Korea · Recruiting

  • Research Site

    Seoul, South Korea · Recruiting

  • Research Site

    Seoul, South Korea · Recruiting

  • Research Site

    Seoul, South Korea · Recruiting

  • Research Site

    Seoul, South Korea · Recruiting

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.